法尼基转移酶抑制剂替吡法尼治疗复发/难治性外周T细胞淋巴瘤的2期试验
这项国际、开放标签、非随机、单臂2期试验评估替吡法尼单药治疗复发/难治性外周T细胞淋巴瘤(PTCL)的疗效与安全性,并探索肿瘤突变谱作为缓解生物标志物。65例患者接受替吡法尼300 mg口服每日两次、每28天周期用21天,总客观缓解率(ORR)为39.7%(95%CI 28.1-52.5),血管免疫母细胞性T细胞淋巴瘤(AITL)亚型ORR为56.3%(95%CI 39.3-71.8)。替吡法尼单药在重度经治复发/难治性PTCL尤其AITL中显示令人鼓舞的临床活性,安全性可控。
要点
- 替吡法尼300 mg口服每日两次、每28天周期用21天,治疗复发/难治性PTCL。
- 总ORR 39.7%,AITL亚型ORR 56.3%,AITL中位DOR 7.8个月。
- 常见替吡法尼相关血液学不良事件为中性粒细胞减少43.1%、血小板减少36.9%、贫血30.8%。
核心结论
- 替吡法尼单药在重度经治的复发/难治性PTCL尤其AITL中显示令人鼓舞的临床活性,安全性可控。
研究设计与样本
- 国际、开放标签、非随机、单臂2期试验,评估替吡法尼单药治疗复发/难治性PTCL的疗效与安全性,并评估肿瘤突变谱作为缓解生物标志物。
- 成人复发/难治性PTCL患者接受替吡法尼300 mg口服每日两次,每28天周期用21天。
- 共入组65例PTCL患者:AITL 38例、PTCL非特指型25例、其他T细胞淋巴瘤2例。
- 主要终点为客观缓解率(ORR);次要终点包括特定亚型的ORR、无进展生存期(PFS)、缓解持续时间(DOR)和不良事件(AE)。
主要发现
- 全部患者ORR为39.7%(95%CI 28.1-52.5),AITL为56.3%(95%CI 39.3-71.8)。
- 中位PFS总体为3.5个月(95%CI 2.1-4.4),AITL为3.6个月(95%CI 1.9-8.3)。
- 中位DOR为3.7个月(95%CI 2.0-15.3),AITL最长,为7.8个月(95%CI 2.0-16.3)。
- 中位总生存期为32.8个月(95%CI 14.4至不可评估)。
- 替吡法尼相关血液学AE可控,包括中性粒细胞减少43.1%、血小板减少36.9%、贫血30.8%;其他替吡法尼相关AE包括恶心29.2%和腹泻27.7%;发生1例治疗相关死亡。
关键数值与推荐
- AITL替吡法尼缓解组RhoA、DNMT3A、IDH2突变分别见于60%、33%、27%,非缓解组分别为36%、9%、9%。
- 原文中位PFS总体处写作「954% CI」,原文此处表述有矛盾,按上下文应为95%CI。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A phase 2, international, open-label, nonrandomized, single-arm trial was conducted to evaluate the efficacy and safety of tipifarnib, a farnesyltransferase inhibitor, as monotherapy for relapsed/refractory peripheral T-cell lymphoma (PTCL) and to evaluate tumor mutation profile as a biomarker of response. Adults with relapsed/refractory PTCL received tipifarnib 300 mg orally twice daily for 21 days in a 28-day cycle. The primary end point was objective response rate (ORR); secondary end points included ORR, progression-free survival (PFS), duration of response (DOR), and adverse events (AEs) in specific subtypes. Sixty-five patients with PTCL were enrolled: n = 38 angioimmunoblastic T-cell lymphoma (AITL), n = 25 PTCL not otherwise specified, and n = 2 other T-cell lymphomas. The ORR was 39.7% (95% confidence interval [CI], 28.1-52.5) in all patients and 56.3% (95% CI, 39.3-71.8) for AITL. Median PFS was 3.5 months overall (954% CI, 2.1-4.4), and 3.6 months (95% CI, 1.9-8.3) for AITL. Median DOR was 3.7 months (95% CI, 2.0-15.3), and greatest in patients with AITL (7.8 months; 95% CI, 2.0-16.3). The median overall survival was 32.8 months (95% CI, 14.4 to not applicable). Tipifarnib-related hematologic AEs were manageable and included neutropenia (43.1%), thrombocytopenia (36.9%), and anemia (30.8%); other tipifarnib-related AEs included nausea (29.2%) and diarrhea (27.7%). One treatment-related death occurred. Mutations in RhoA, DNMT3A, and IDH2 were seen in 60%, 33%, and 27%, respectively, in the AITL tipifarnib responder group vs 36%, 9%, and 9% in the nonresponder group. Tipifarnib monotherapy demonstrated encouraging clinical activity in heavily pretreated relapsed/refractory PTCL, especially in AITL, with a manageable safety profile. This trial was registered at www.ClinicalTrials.gov as #NCT02464228.
引用
- Witzig T, Sokol L, Kim WS, et al. Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma. Blood Adv. 2024. PMID: 38991123. doi:10.1182/bloodadvances.2024012806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。